Glycotope Overview
- Year Founded
-
2000
- Status
-
Acquired/Merged
- Employees
-
25
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$142M
Glycotope General Information
Description
Developer of a glycobiology technology designed to address tumor-specific glycol-epitope targets. The company's technology is focused on the development of clinical and pre-clinical programs with an array of modes of action to provide an offering in the immuno-oncology and oncology space, enabling doctors to treat various types of cancer with human glycosylation.
Contact Information
Website
www.glycotope.com(Operating Subsidiary)
Corporate Office
- Robert-Roessle-Strasse 10
- 13125 Berlin
- Germany
Corporate Office
- Robert-Roessle-Strasse 10
- 13125 Berlin
- Germany
Glycotope Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 03-Jul-2024 | $142M | Completed | Clinical Trials - Phase 1 | ||
| 5. Secondary Transaction - Private | 01-May-2023 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC | 08-Oct-2015 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC | 12-Mar-2014 | Completed | Clinical Trials - Phase 1 | |||
| 2. Later Stage VC | 03-Nov-2007 | $57.1M | $57.1M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC | 01-Jan-2001 | Completed | Startup |
Glycotope Comparisons
Industry
Financing
Details
Glycotope Competitors (16)
One of Glycotope’s 16 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Symphogen | Formerly VC-backed | Ballerup, Denmark | ||||
| DelSiTech | Venture Capital-Backed | Turku, Finland | ||||
| Ability Pharma | Private Equity-Backed | Cerdanyola, Spain | ||||
| Aura Biosciences | Formerly VC-backed | Boston, MA |
Glycotope Patents
Glycotope Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250074999-A1 | Antibodies against lypd3 | Pending | 16-Mar-2022 | ||
| WO-2023175117-A1 | Antibodies against lypd3 | Inactive | 16-Mar-2022 | ||
| WO-2022002887-A1 | Humanized antibodies against lewis y | Inactive | 30-Jun-2020 | ||
| CA-3100745-A1 | Anti-muc1 antibody | Pending | 18-May-2018 | ||
| EP-3794041-A1 | Anti-muc1 antibody | Active | 18-May-2018 | C07K16/3092 |
Glycotope Signals
Glycotope Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Eckert Life Science Accelerator | Accelerator/Incubator | Minority | ||
| Hexal | Corporation | Minority | ||
| Jossa Arznei | VC-Backed Company | Minority | ||
| Octapharma | Corporation | Minority | ||
| Angel (individual) | Minority |
Glycotope Acquisitions (1)
Glycotope’s most recent deal was a Merger/Acquisition with Orpegen Pharma. The deal was made on 24-Jul-2008.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Orpegen Pharma | 24-Jul-2008 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology |
Glycotope Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Glycotope Biotechnology (Recombinant Technology) | Heidelberg, Germany | 2008 |
Glycotope FAQs
-
When was Glycotope founded?
Glycotope was founded in 2000.
-
Where is Glycotope headquartered?
Glycotope is headquartered in Berlin, Germany.
-
What is the size of Glycotope?
Glycotope has 25 total employees.
-
What industry is Glycotope in?
Glycotope’s primary industry is Drug Discovery.
-
Is Glycotope a private or public company?
Glycotope is a Private company.
-
What is the current valuation of Glycotope?
The current valuation of Glycotope is .
-
What is Glycotope’s current revenue?
The current revenue for Glycotope is .
-
How much funding has Glycotope raised over time?
Glycotope has raised $285M.
-
Who are Glycotope’s investors?
Eckert Life Science Accelerator, Hexal, Jossa Arznei, Octapharma, and have invested in Glycotope.
-
Who are Glycotope’s competitors?
Ayala Pharmaceuticals, Symphogen, DelSiTech, Ability Pharma, and Aura Biosciences are some of the 16 competitors of Glycotope.
-
When was Glycotope acquired?
Glycotope was acquired on 03-Jul-2024.
-
Who acquired Glycotope?
Glycotope was acquired by Pentixapharm.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process